Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy

Gastric Cancer

Volumn 20, Issue 1, 2017, Pages 175-181

  Shitara, Kohei ^a   Chin, Keisho ^b   Yoshikawa, Takaki ^c   Katai, Hitoshi ^d   Terashima, Masanori ^e   Ito, Seiji ^f   Hirao, Motohiro ^g   Yoshida, Kazuhiro ^h   Oki, Eiji ⁱ   Sasako, Mitsuru ^j   Emi, Yasunori ^k   Tsujinaka, Toshimasa ^l  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

^c KANAGAWA CANCER CENTER   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

^e SHIZUOKA CANCER CENTER   (Japan)

^f AICHI CANCER CENTER HOSPITAL   (Japan)

^g OSAKA NATIONAL HOSPITAL   (Japan)

^h GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ KYUSHU UNIVERSITY   (Japan)

^j HYOGO COLLEGE OF MEDICINE   (Japan)

^k SAISEIKAI FUKUOKA GENERAL HOSPITAL   (Japan)

^l Kaizuka City Hospital   (Japan)

more..

Author keywords

Adjuvant chemotherapy; Oxaliplatin; S 1; S 1 and oxaliplatin; Stage III gastric cancer

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; C REACTIVE PROTEIN; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; OXALIPLATIN; ANTINEOPLASTIC AGENT; DRUG COMBINATION; OTERACIL; PLATINUM COMPLEX; S 1 (COMBINATION); TEGAFUR;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; EMPYEMA; FATIGUE; FEMALE; GASTRECTOMY; HUMAN; HYPERTENSION; HYPOKALEMIA; INFUSION RELATED REACTION; LEUKOPENIA; LUNG EMBOLISM; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SENSORY NEUROPATHY; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; VOMITING; ADJUVANT CHEMOTHERAPY; CLINICAL TRIAL; DRUG COMBINATION; FOLLOW UP; MIDDLE AGED; PATHOLOGY; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; GASTRECTOMY; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; OXONIC ACID; PROGNOSIS; PROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE; TEGAFUR; YOUNG ADULT;

EID: 84949493623     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-015-0581-1     Document Type: Article

References (11)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0. Cancer Incidence Mortality Worldwide. IARC CancerBase. 2012. http://globocan.iarc.fr/default.aspx. Accessed 4 April 2015.
2. Ministry of Health, Labour and Welfare. Summary of vital statistics 2013. http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/kakutei13/dl/11_h7.pdf. Accessed 4 Apr 2015.
3. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines (ver. 4). Tokyo: Kanehara publication. 2014.
4. Shirasaka T. Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. Jpn J Clin Oncol. 2009;39:2–15.
5. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.
6. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387–93.
7. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315–21.
8. Takahari D, Hamaguchi T, Yoshimura K, Katai H, Ito S, Fuse N, et al. Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer. Cancer Chemother Pharmacol. 2011;67:1423–8.
9. Yamada Y, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Sugimoto N, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann Oncol. 2015;26:141–8.
10. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma (14th edition). Tokyo: Kanehara publication. 2010.
11. Koizumi W, Takiuchi H, Yamada Y, Boku N, Fuse N, Muro K, et al. Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study). Ann Oncol. 2010;21:1001–5.